Diaz MJ, Tran JT, Choo Z-N, Root KT, Batchu S, Milanovic S, Ladehoff L, Fadil A, Lipner SR.  2023.  Genomic subtypes of cutaneous melanoma have distinct metabolic profiles: A single-cell transcriptomic analysis.. Arch Dermatol Res. 315(10):2961-2965.

Zhang M, Di Martino JS, Bowman RL, Campbell NR, Baksh SC, Simon-Vermot T, Kim IS, Haldeman P, Mondal C, Yong-Gonzales V et al..  2018.  Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins.. Cancer Discov. 8(8):1006-1025.

Knauf JA, Luckett KA, Chen K-Y, Voza F, Socci ND, Ghossein R, Fagin JA.  2018.  Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers.. J Clin Invest. 128(9):4086-4097.

Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Mai TThi, Chaudhary N, Riely GJ, Li BT, Scott K et al..  2017.  An approach to suppress the evolution of resistance in BRAF-mutant cancer.. Nat Med. 23(8):929-937.

Anelli V, Villefranc JA, Chhangawala S, Martinez-McFaline R, Riva E, Nguyen A, Verma A, Bareja R, Chen Z, Scognamiglio T et al..  2017.  Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression.. Elife. 6

Theodosakis N, Micevic G, Langdon CG, Ventura A, Means R, Stern DF, Bosenberg MW.  2017.  p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis.. J Invest Dermatol. 137(10):2187-2196.

McFadden DG, Vernon A, Santiago PM, Martinez-McFaline R, Bhutkar A, Crowley DM, McMahon M, Sadow PM, Jacks T.  2014.  p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.. Proc Natl Acad Sci U S A. 111(16):E1600-9.